Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility
January 16 2018 - 7:00AM
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small
molecule innovator and generic Active Pharmaceutical Ingredients
(APIs), today held an opening ceremony with AstraZeneca, at its
Karlskoga, Sweden site to mark the commencement of a long-term
manufacturing agreement between the two companies for a key
intermediate.
The announcement follows the completion, in
2017, of both a large-scale, multi-purpose capacity expansion which
also includes hydrogenation capabilities and a dedicated continuous
flow production unit capable of producing multiple metric tons of
high purity advanced intermediates per annum at the Karlskoga
facility.
Speaking at the ceremony, Juliette White, VP
Global External Sourcing, AstraZeneca, commented, “Cambrex was
selected as our manufacturing partner on this long-term
intermediate supply agreement as they clearly demonstrated a robust
technically and commercially attractive solution, as well as having
a good track record in terms of performance and delivery.” She
added, “We look forward to a successful collaboration with
Cambrex.”
Shawn Cavanagh, COO of Cambrex, stated, “We have
an excellent relationship with AstraZeneca dating back to the 1950s
and are excited to partner with them on the long-term production of
several important products.” He added, “We will continue to invest
in capabilities, technology and appropriate capacity at the
Karlskoga site in line with AstraZeneca’s ambitious targets and
on-going customer demand.”
About
Cambrex
Cambrex Corporation is an innovative life
sciences company that provides products, services and technologies
to accelerate the development and commercialization of small
molecule therapeutics. The Company offers Active
Pharmaceutical Ingredients (APIs), advanced intermediates and
enhanced drug delivery products for branded and generic
pharmaceuticals. Development and manufacturing capabilities include
enzymatic biotransformations, high potency APIs, high energy
chemical synthesis and controlled substances.
Cambrex’s Karlskoga, site develops and
manufactures small molecule APIs, new chemical entities (NCEs) and
intermediates from grams to tons, through all phases of the drug
lifecycle.
Home to a team of more than 400 employees, the
site is comprised of a combination of GMP and non-GMP work,
providing classic and advanced chemistry capabilities, continuous
processes and high energy chemistry expertise.
The site also features a wide range of flexible
manufacturing facilities including kilo scale, pilot scale and
large scale commercial production plants.
For more information, please visit
www.cambrex.com.
About AstraZeneca
AstraZeneca is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular & Metabolic Diseases and Respiratory.
The Company also is selectively active in the areas of
autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide.
For more information, please visit
www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Contact: Alex
Maw
Director, Marketing and Communications,
Cambrex
Tel: +44 7803 443
155
Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Apr 2023 to Apr 2024